DOCETAXEL NEAPOLIS 80 MG BT 1

Breast cancer:

1- Doxetal (docetaxel) in combination with doxorubicin and cyclophosphamide is indicated for adjuvant treatment of operable breast cancer, in patients with nodal involvement.

2- Doxetal (docetaxel) in combination with doxorubicin is indicated for the treatment of locally advanced or metastatic breast cancer in patients who have not received cytotoxic chemotherapy before for this condition.

3- Doxetal (docetaxel) is indicated as monotherapy in the treatment of patients with locally advanced or metastatic breast cancer after failure of a cytotoxic chemotherapy that included an anthracycline or an alkylating agent.

4- Doxetal (docetaxel) in combination with capecitabine is indicated for the treatment of locally advanced or metastatic breast cancer after cytotoxic chemotherapy that included an anthracycline.

Non-small cell lung cancer:

1- Doxetal (docetaxel) is indicated for the treatment of locally advanced or metastatic non-small cell lung cancer, after failure of previous chemotherapy.

2- Doxetal (docetaxel) in combination with cisplatin is indicated for the treatment of unresectable, locally advanced or metastatic non-small cell lung cancer, in patients who have not received chemotherapy before for this indication.

Prostate cancer:

Doxetal (docetaxel) in combination with prednisone or prednisolone is indicated for the treatment of metastatic hormone-resistant prostate cancer.

Upper aerodigestive tract cancer Doxetal (docetaxel), in combination with cisplatin and 5-Fluorouracil, is indicated for induction treatment of locally advanced squamous cell carcinomas, of the upper aerodigestive tract. -Gastric cancer: Doxetal (docetaxel), in combination with cisplatin and 5-Fluorouracil, is indicated for the treatment of metastatic gastric adenocarcinoma, including adenocarcinoma of the esophagogastric junction, in patients not previously treated with chemotherapy for their metastatic disease.